Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this six-year study of a Saudi cohort, oral tofacitinib showed favorable long-term effectiveness for patients with AA, with manageable adverse events requiring regular monitoring.

This review discusses the bioactive compounds and biological activities of Polygonum multiflorum Thunb. and highlights concerns about its hepatotoxicity, but reports no new clinical results.

In this case study, an 18-year-old woman's triangular alopecic patch diagnosed as temporal triangular alopecia was considered non-progressive and had no impact on her quality of life, so no treatment was initiated.

This article explores the therapeutic potential of TECAR therapy for physiotherapy, highlighting its non-invasive nature and ability to provide analgesic, anti-inflammatory, and tissue healing effects across various conditions with minimal side effects when applied correctly.

The study observed that Tai Chi and Wuqinxi, when combined with antihypertensive medication, might be particularly effective in lowering systolic and diastolic blood pressure, respectively, suggesting they could be prioritized as treatment options.

This study developed a high-throughput method that identifies bioactive chemicals influencing DHT production in prostate cancer cells, with potential nutraceutical candidates including fucoxanthin, phenethyl caffeate, and Curcuma longa L. extract.

In this study, tofacitinib treatment significantly reduced hair loss on the head and body, as well as nail involvement, in patients with alopecia areata over 18 months, with minimal side effects reported.

This study found that tofacitinib and baricitinib, when administered with unorthodox weight-stratified dosing in pediatric patients with moderate-to-severe AA, showed comparable efficacy and tolerability, though baricitinib's efficacy decreased with non-standard dosing.

This study describes the ongoing HABIT study in Taicang, China, which aims to identify risk factors and the relationship between cardiovascular and neurodegenerative diseases among 10,357 adults, by collecting and analyzing long-term data on health, lifestyle, and biological specimens. Results are not yet available.

This study found that tofacitinib may be effective for treating pediatric rheumatic diseases, with especially promising results in patients with autoinflammatory diseases, arthritis and alopecia, and juvenile dermatomyositis.

Tofacitinib helped regrow hair in a patient with severe hair loss and improved their quality of life without side effects.

In this study, ritlecitinib, an oral JAK3/TEC inhibitor, was evaluated for safety in patients aged 12 and older with alopecia areata across four clinical trials up to 36 months, showing a safety profile with reported adverse events and lab abnormalities summarized per dosing groups.

This study concluded that Quzhi Fangtuo Pill significantly improved outcomes in early androgenetic alopecia compared to Chuzhi Shengfa Pill, with an effective rate of 60.42% versus 22.22%.

In this case report, a 42-year-old Yemeni man who consumed khat presented with elevated liver enzymes and fatty liver, raising concerns about khat's potential role in accelerating liver damage, especially when obesity and fatty liver disease are already present.

This study assessed oral tofacitinib's effectiveness and safety in treating different forms of alopecia, finding that 80% of patients experienced hair regrowth improvements over 24 weeks with no adverse events reported.

In this study, tofacitinib showed promising efficacy and safety for biologic-naïve elderly patients with moderate-to-severe ulcerative colitis, achieving steroid-free remission and clinical response over 52 weeks.

This study found that the Qing Cuo Formula significantly reduced serum androgen and inflammatory cytokine levels in hamsters with damp-heat acne and identified potential molecular mechanisms and active compounds involved.

In this report, two adult patients with Tatton-Brown-Rahman syndrome exhibited new cardiac features, such as atrial fibrillation and ventricular and atrial dilatation, highlighting the importance of cardiovascular follow-up in adults with this condition.

In this study, sublingual tofacitinib achieved a longer estimated half-life than oral administration in treatment-resistant alopecia areata patients, potentially supporting daily dosing; overall treatment response was modest.

This study found that formulating raloxifene in nano-lipid carriers significantly enhanced its permeation and cytotoxicity against cancer cells compared to raw raloxifene.

This study evaluated the effectiveness and safety of ritlecitinib in patients aged 12 or older with alopecia totalis or universalis, finding higher hair regrowth response rates compared to placebo at 24 weeks, with continued improvement and acceptable safety through 48 weeks.

This study found that octahydrobenzo[c]quinolizin-3-one derivatives, particularly compound 3, were potent and selective inhibitors of the enzyme 5α-reductase type 1.

A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.

This study revealed that tofacitinib may inhibit CD8⁺ T cell infiltration in alopecia areata by modulating the linoleic acid metabolism-Mg²⁺ pathway, providing new insights for potential treatments and diagnosis.

In this case report, a young adult male with resistant alopecia areata showed nearly 90% hair regrowth after 3 months of treatment with tofacitinib, alongside biotin supplementation, without any side effects observed.

In this study, a taurine-based ionic liquid was developed to effectively penetrate the skin barrier and deliver antioxidants to hair follicles, reducing oxidative stress and promoting hair regrowth in an androgenic alopecia animal model.

This study found that tofacitinib effectively induced hair regrowth in 62.2% of severe alopecia areata patients in Saudi Arabia after six months, with higher baseline Severity of Alopecia Tool scores and past steroid use linked to reduced response.

This study found that oral tofacitinib was effective and well tolerated for treating alopecia areata in most pediatric patients, with nearly 73% experiencing hair regrowth.

This study found that tofacitinib was an effective and better-tolerated treatment for moderate-to-severe AA compared to SCs, though its efficacy decreased in patients with disease episodes longer than two years.